

Extension of a Retrospective Evaluation of a National Alternate Site Infusion Provider's Approach to Parenteral Ibalizumab-uiyk Compliance

DEBORAH DAHLKE, PharmD
Option Care Health - Bannockburn, Illinois

Introduction

Ibalizumab-uiyk is used in conjunction with oral antiretroviral therapy (ART), approved for individuals with multidrug resistant HIV-1 who are failing their current ART therapy.¹

Studies in 2019 and 2021 showed ibalizumab-uiyk compliance of 85% and 97% combined with ART regimen compliance of 89% and 94% using a compliance-focused care model leading to conclusions of improved compliance during the pandemic.^{2,3} Here, we present an extended analysis to include all patients treated with ibalizumab-uiyk under this model since FDA approval.

Objective

The objective of this study was to determine whether a compliance-focused care model facilitates ibalizumab-uiyk and ART regimen compliance.

Methods

A retrospective analysis of ibalizumab-uiyk treated patients. Data collection period from May 2018 through February 2021, which included evaluation of subjects' electronic records for ART compliance, ibalizumab-uiyk dispense history, and overall ibalizumab-uiyk service status. Outcome parameters include overall compliance rate of ibalizumab-uiyk based on dispense history, compliance to ART regimen, and ibalizumab-uiyk discontinuation rate.

Infusions were considered non-compliant if an ibalizumab-uiyk maintenance dose was missed by greater than 3 days. Furthermore, missed doses and service discontinuation reasons were classified to evaluate for patient non-compliance. Patients were considered compliant on ART regimen when documented by pharmacy staff as compliant in clinical assessments.

Results

Results of this study support the original objective. Study patients are shown in Table 1.

Overall ibalizumab-uiyk compliance was 98% [Figure 1]. Of the 2% of doses missed, 28.4% were missed due to patient non-compliance [Figure 2]. Ibalizumab-uiyk service status classification showed 90% of patients continued ibalizumab-uiyk as expected or transitioned to alternate therapy with 9.2% of discontinued services due to patient non-compliance [Figure 3]. Compliance to ART regimen was determined to be 89% [Figure 4, 5].

Average treatment duration was 1.4 years with a median of 1.3 years.

Table 1: Inclusion Data

Inclusion Data	Number
Total Infusions	3528
Patients	130
Gender	Number (%)
Male	101 (77.7)
Female	29 (22.3)
Age	Years (SD)
Median	64 (12.6)
Range	23-79 years

Figure 1: Total Ibalizumab-uiyk Infusions




Figure 2: Missed Ibalizumab-uiyk Infusions (N=81)




Figure 3: Ibalizumab-uiyk Infusion Service Status (N=130)




Figure 4: Oral ART Compliance





Figure 5: Oral ART Compliance



Discussion

Utilization of a compliance-focused care model resulted in ibalizumab-uiyk and ART compliance of 98% and 89% respectively. Service status evaluation showed that 90% of patients continued treatment, which is consistent with the 2019 retrospective study.

Conclusion

Results support utilization of a previously studied compliance-focused clinical care model for ibalizumab-uiyk, maintained compliance rates over an average of 1.4 years among a multidrug resistant HIV-1 infected population.

References

- ¹ Trogarzo. Package insert. Theratechnologies; 2018.
- ² Miller, M. & Andrusko-Furphy, K. (2019, November). A retrospective evaluation of a national home infusion provider's approach to medication adherence of parenteral ibalizumab-uiyk. Poster presented at the 17th Annual European AIDS Conference, Basel, Switzerland.
- ³ Dahlke, D. (2021, April). A retrospective cohort to demonstrate the impact of coronavirus disease (COVID-19) on compliance rates amount a home infusion provider's population of multidrug resistant hiv-1 infected patients. Poster presented at the 2021 Annual NHIA conference, Austin, TX.

Disclosure

Authors of this presentation have the following to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Deborah Dahlke; Nothing to disclose.